NVIDIA and Lilly CEOs Unveil 'Blueprint of Possibility' for AI-Driven Drug Discovery in Joint Innovation Lab Initiative
NVIDIA
Artificial Intelligence Computing Service Provider
At the JPMorgan Healthcare Conference, David A. Ricks, Chairman and CEO of Eli Lilly, held a discussion with Jensen Huang, Founder and CEO of NVIDIA, to exchange views on the newly established groundbreaking AI Joint Innovation Lab and the future of biopharmaceuticals.
In a recent fireside chat with David A. Ricks, Chairman and CEO of Eli Lilly, NVIDIA Founder and CEO Jensen Huang stated that NVIDIA and Eli Lilly are co-creating a “blueprint for the future possibilities of drug discovery.”
This conversation took place during the J.P. Morgan Healthcare Conference in San Francisco, focusing on the industry’s first AI joint innovation laboratory established by NVIDIA and Eli Lilly.
Jensen Huang stated, “We are systematically bringing together the brightest minds from the fields of drug discovery and computer science. We aim to build a laboratory with sufficient expertise and scale to attract scientific elites who are truly committed to lifelong exploration in this interdisciplinary domain.”
This initiative will combine Eli Lilly’s global leadership and expertise in the pharmaceutical industry with NVIDIA’s pioneering advancements in artificial intelligence to jointly address one of humanity’s most significant challenges: modeling the complexity of biology. Over a five-year period, the two companies will invest up to $1 billion in talent development, infrastructure, and computing power to support a new laboratory located in the San Francisco Bay Area.
In the Fireside Chat, Dai Wenrui reviewed the arduous journey of drug development and explored the potential of AI to revolutionize the drug discovery cycle.
Jensen Huang and Dave Ricks also discussed Eli Lilly’s long history of leveraging computational technologies in pharmaceutical research, as well as how age-related brain diseases are becoming the next frontier in drug development.
NVIDIA Appears at J.P. Morgan Healthcare Conference
NVIDIA’s full-stack AI platform is accelerating the creation and deployment of leading foundation models in the fields of digital biology and drug discovery. To recognize recent significant advancements, Jensen Huang paid tribute to more than a dozen industry pioneers and the AI models they have pioneered at the J.P. Morgan Healthcare Conference.
Jensen Huang stated, “Over the past decade, we have driven a million-fold leap in AI performance. I believe that in the next ten years, you will experience a journey as remarkable as the one our generation has undergone... As a New Year’s gift, I am presenting each of you with a DGX Spark to thank you for your contributions to the industry and the future of humanity.”
At the J.P. Morgan Healthcare Conference, more than ten pioneers in the fields of AI and drug development were presented with NVIDIA DGX Spark systems personally signed by Jensen Huang, Founder and CEO of NVIDIA.
During the conference, NVIDIA also announced a major expansion of its AI-driven biology and drug discovery platform, NVIDIA BioNeMo.
NVIDIA also highlighted its collaboration with Thermo Fisher Scientific, a leader in instruments and equipment, to build autonomous laboratory infrastructure using NVIDIA’s full-stack AI computing technology. Additionally, NVIDIA showcased the work of Multiply Labs, a San Francisco-based startup that provides end-to-end robotic systems to automate large-scale cell therapy production.
The above is the abstract. Click “Read Full Article” or scan the QR code below to read the complete content:
